Cambridge, United Kingdom · Founded 2019 · Privately Held (backing)
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. LoQus23 Therapeutics is based in Cambridge, United Kingdom and was founded in 2019. Its last known valuation is $61.4 million. It has raised $67.2 million.
Last price · $/share
—
Implied valuation
$61.4M
Total raised
$67.2M
Last round
—
No prints on record
No secondary trades in LoQus23 Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of LoQus23 Therapeutics with a free account
·Watch LoQus23 Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of LoQus23 Therapeutics stock.
